BRAIN CANCER

HER2 Breast Cancer

BREAST CANCER

Bladder Cancer

Prostate Cancer

Renal Cell Carcinoma

GENITOURINARY CANCERS

Liquid Biopsies

GENOMIC TESTING

Colorectal Cancer

GIST

Gastric Cancer

GI CANCERS

Cervical Cancer

Endometrial Cancer

Ovarian Cancer

GYNECOLOGIC CANCERS

HEAD & NECK CANCERS

Bone Marrow & Stem Cell Transplant

HEMATOLOGY

CAR T-Cell Therapy

IMMUNOTHERAPY

Chronic Lymphocytic Leukemia

Chronic Myeloid Leukemia

LEUKEMIAS

Biomarker-Driven Lung Cancer

EGFR+ Lung Cancer

MET-Targeted Therapy

Small Cell Lung Cancer

LUNG CANCER

DLBCL

Follicular Lymphoma

Mantle Cell Lymphoma

LYMPHOMAS

MPNs

MULTIPLE MYELOMA

NTRK GENE FUSIONS

SARCOMA

Melanoma

SKIN CANCERS

THYROID CANCERS

NEWS

All News

FDA Briefs

Oncology Icons

Special Reports

The Targeted Pulse

Voices from the Field

CONFERENCES

Conference Coverage

Conference Listing

Data Dialogue with the Oncology Brothers

MEDIA

All Videos

Case-Based Peer Perspectives

Expert Perspective Virtual Tumor Board

Interviews

Investigator Perspectives

Medical World News

Pivotal Practice Views with the Oncology Brothers

Podcasts

Precision Medicine

Speaking Out

PUBLICATIONS

All Publications

Evolving Paradigms

Peers & Perspectives in Oncology

Targeted Therapies in Oncology

CASE-BASED ROUNDTABLE

PARTNERS

RESOURCES

CME/CE

Clinical Trials

Precision Medicine Perspectives

Press Releases

Treatment Resources

SUBSCRIBE

Targeted Oncology provides news, videos, and reviews on the rapidly evolving world of targeted therapies and immunotherapy for oncologists treating patients in a community setting.

About Us

Advertise

Contact Us

CureToday.com

CancerNetwork.com

OncLive.com

OncNursingNews.com

Do Not Sell My Information

Privacy

Terms & Conditions

Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways

Facebook

Linkedin

YouTube

Instagram

Featured Clinical Focus

BTK Inhibitors: In-Focus

Bone Marrow & SCT

EGFR-Positive Lung Cancer

Lung Cancer

Multiple Myeloma

Thyroid Cancers

Clinical Focus

Brain Cancer

Breast Cancer

Gastrointestinal Cancer

Genitourinary Cancers

Gynecologic Cancers

Head & Neck Cancers

Hematology

Leukemias

Lymphomas

Sarcoma

Skin Cancers

Spotlight

1rem

View

Emerging Treatment Updates: Antibody Drug Conjugates in Relapsed/Refractory Follicular Lymphoma 

Video Series

Key Considerations for the Evolving Treatment Landscape for Relapsed/Refractory Follicular Lymphoma

Video content above is prompted by the following:

Other antibody-drug conjugates have been examined in the relapsed/refractory follicular lymphoma (R/R FL) space in combination with rituximab.

Polatuzumab vedotin + rituximab and pinatuzumab vedotin + rituximab. In the R/R FL population, how do these agents perform?

Given the data update from Alderuccio et al. ASH 2024, comment on how loncastuximab + rituximab could play a role in the treatment landscape for R/R FL. What patient considerations are critical to note?

Videos

Juan Pablo Alderuccio, MD, explores the evolving treatment landscape of relapsed/refractory follicular lymphoma, highlighting how novel combinations like loncastuximab tesirine plus rituximab address key therapeutic challenges through complementary targeting of CD19 and CD20, with initial evidence supporting this approach in the pursuit of improved patient outcomes.

A panelist discusses how managing relapsed/refractory follicular lymphoma (R/R FL) requires carefully weighing multiple factors including patient fitness, prior therapies, duration of response, symptoms, and treatment goals while confronting challenges like treatment resistance, cumulative toxicities, and the lack of a clear standard of care sequence.

An Overview of the Current Treatment Landscape for R/R FL

A panelist discusses how loncastuximab tesirine, an antibody-drug conjugate targeting CD19, shows promise in combination with rituximab for R/R FL based on its complementary mechanism of action targeting CD19-expressing B -cells, demonstrated single-agent activity in early studies, and preliminary evidence suggesting potential synergy with anti-CD20 therapy in this setting.

Exploring ADC/Antibody Combination Therapies in Development for R/R FL

A panelist discusses how a new phase 2 study investigating the combination of loncastuximab tesirine plus rituximab in patients with relapsed/refractory follicular lymphoma aims to build upon earlier promising results by evaluating efficacy, safety, and durability of response in a larger patient population.

An Investigator-Initiated Study of Loncastuximab Tesirine Plus Rituximab for the Treatment of R/R FL  

A panelist discusses updates from from the phase 2 study of loncastuximab + rituximab from ASH 2024. 

Recent Safety and Efficacy Updates from the Investigator Initiated Study of Loncastuximab tesirine + Rituximab for the Treatment of R/R FL 

A panelist discusses how various antibody-drug conjugates, including polatuzumab vedotin, pinatuzumab vedotin, and loncastuximab, have been studied in combination with rituximab for relapsed/refractory follicular lymphoma. Recent data from ASH 2024 highlight important patient considerations for these treatment approaches.

Key Considerations for the Evolving Treatment Landscape for Relapsed/Refractory Follicular Lymphoma

EP: 1.An Overview of the Current Treatment Landscape for R/R FL

EP: 2.Exploring ADC/Antibody Combination Therapies in Development for R/R FL

EP: 3.An Investigator-Initiated Study of Loncastuximab Tesirine Plus Rituximab for the Treatment of R/R FL

EP: 4.Recent Safety and Efficacy Updates from the Investigator Initiated Study of Loncastuximab tesirine + Rituximab for the Treatment of R/R FL

EP: 5.Key Considerations for the Evolving Treatment Landscape for Relapsed/Refractory Follicular Lymphoma